Currrent Issue: Volume 3, Number 4, 2015


Article

Gemcitabine and Cisplatin Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report

1Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van,Turkey

2Department of Radiology, Van Training and Research Hospital, Van, Turkey

3Department of Internal Medicine, Van Training and Research Hospital, Van, Turkey

4Department of Anesthesiolgy, Van Training and Research Hospital, Van, Turkey

5Department of Radiology, Yuzuncu Yil University Medical Faculty, Van,Turkey


American Journal of Cancer Prevention. 2015, 3(4), 74-76
doi: 10.12691/ajcp-3-4-2
Copyright © 2015 Science and Education Publishing

Cite this paper:
Erkan Dogan, Cemile Ayse Gormeli, Mehmet Fatih Ozbay, Edip Gonullu, Alper Can, Harun Arslan. Gemcitabine and Cisplatin Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report. American Journal of Cancer Prevention. 2015; 3(4):74-76. doi: 10.12691/ajcp-3-4-2.

Correspondence to: Erkan  Dogan, Department of Medical Oncology, Yuzuncu Yil University Medical Faculty, Van,Turkey. Email: dr_erkandogan@hotmail.com

Abstract

Background: Reversible Posterior Leukoencephalopathy Syndrome (RPLS) is a rare clinic-radiological condition. The clinical characteristics of this syndrome are headache, seizures, visual disturbances, confusion, and changes in mental status and focal neurological signs. The radiological characteristic of RPLS is bilateral symmetrical reversible vasogenic edema in the grey and white matter of the posterior part of the parietal-occipital lobes, consistent with hyperintensity in magnetic resonance imaging and computer tomography scans of the brain. Herein we report RPLS during the therapy with gemcitabine and cisplatin in a female patient with pancreatic cancer. Case Report: A 66-year-old female patient was admitted to the hospital because of abdominal pain. The results of computer tomography scans of the abdomen showed a 6-cm mass lesion in the tail of the pancreas and multiple metastatic lesions in the liver. A ‘tru-cut’ biopsy of the liver lesion proved to be consistent with adenocarcinoma. A combination chemotherapy regimen consisting of gemcitabine and cisplatin was planned. During this therapy, RPLS developed as a complication. Subsequent administration of chemotherapy was cancelled, and antihypertensive and anti-edema treatments were begun. Following this treatment the patient’s symptoms rapidly improved. There was a dramatic decline in vasogenic edema in control MRI scans which were performed a week later. Conclusion: Failure to diagnose the RPLS and correct the precipitating cause may result in catastrophic permanent brain injury or even death.

Keywords

References

[1]  Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome, N Engl J Med, 334 (8), 494-500, 1996.
 
[2]  Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol, 27 (4), 1436-7, 2010.
 
[3]  Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.Oncologist, 12 (11), 1332-5, 2007.
 
[4]  Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc, 85(5), 427-32, 2010.
 
[5]  Port JD, Beauchamp NJ Jr. Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics, 18 (2), 353-67, 1998.
 
Show More References
[6]  Bartynski WS, Boardman JF. Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 29 (3), 447-55, 2008.
 
[7]  Sclafani F, Giuseppe G, Mezynksi J, Collins C, Crown J. Reversible posteriorleukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol, 30 (26), e257-9, 2012.
 
[8]  Femia G, Hardy TA, Spies JM, Horvath LG. Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pac J Clin Oncol, 8 (2), 115-22, 2012.
 
Show Less References

Article

Solitary Plasmacytoma in the Oral cavity: A Case Report

1Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran


American Journal of Cancer Prevention. 2015, 3(4), 72-73
doi: 10.12691/ajcp-3-4-1
Copyright © 2015 Science and Education Publishing

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi, Jalil Hamidi. Solitary Plasmacytoma in the Oral cavity: A Case Report. American Journal of Cancer Prevention. 2015; 3(4):72-73. doi: 10.12691/ajcp-3-4-1.

Correspondence to: Masoud  Sadeghi, Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: sadeghi_mbrc@yahoo.com

Abstract

Background: The plasma cell neoplasms may present in soft tissue as extramedullary plasmacytomas, in bone as a solitary plasmacytoma of bone, or as part of the multifocal disseminated disease multiple myeloma. The aim of study is to report solitary plasmacytoma in the oral cavity in a male patient. Case Report: A 65-year-old male was presented to our Clinic with hypertension, high fever and loss of balance. He had nine months ago one localized lytic lesion in his thoracic vertebrae T5. The clinical reports showed multiple myeloma for him. After that, He received melphalan and thalidomide for two months. The patients referred to Clinic again with a new oral lesion. In his treatment follow-up and biopsy from his new oral lesion, pathologist reported plasmacytoma. He was treated with radiotherapy(5.000 cGy), than received maintenance consisted of thalidomide 50 mg (VAD). He died after three months from treatment with VAD. Conclusion: The SPB is as part of the multifocal disseminated disease MM. Also, radiotherapy (5.000 cGy) and VAD are not optimal treatments for SPB.

Keywords

References

[1]  Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol. 3(3):255-9.2002.
 
[2]  Dagan R, Morris CG, Kirwan J, Mendenhall WM. Solitary plasmacytoma. Am J Clin Oncol. 32(6):612-7.2009.
 
[3]  Mendenhall WM, Mendenhall CM, Mendenhall NP. Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol. 24(6):395-9.2003.
 
[4]  Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 96(6):2037-44.2000.
 
[5]  Regezi JA, Sciubba JJ, Jordan RCK. Oral Pathology: Clinical Pathologic Correlations. 4th Edn. Philadelphia, W.B. Saunders. 2003.
 
Show More References
[6]  Barros TP, Savilha FM, Amantea DV, Campolongo GD, Neto LB, Alves N, et al. Plasmacytoma in the oral cavity: A case report. Int J Odontostomat. 5(2):115-118. 2011.
 
[7]  Galieni P, Cavo M, Pulsoni A, Avvisati G, Bigazzi C, Neri S, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. Jan .85(1):47-51.2000.
 
[8]  Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park). Jan .14(1):101-8.2000.
 
[9]  Romero IL, Campos FA, Damasceno RW, Vital Filho J, Bison SH. Plasmacytoma of the orbit involving lacrimal gland with secondary transformation into multiple myeloma: case report. Arq Bras Oftalmol. 72(2):236-8.2009.
 
Show Less References